Daniele Amaral

Daniele Amaral is a seasoned professional with extensive experience in commercial and market access strategies within the pharmaceutical industry. Currently serving as the LATAM Regional BU Lead for nemolizumab at Galderma since April 2023, Daniele has previously held significant roles at Amgen including Director of Global Access Strategy for the Hematology pipeline and Reimbursement Director for various intercontinental regions. Daniele's career also includes impactful positions at Janssen Brasil, where leadership spanned strategic affairs and immunology, and at Boehringer Ingelheim, focusing on brand management across multiple therapeutic areas. Earlier professional experience includes an internship at Eli Lilly. Daniele holds a degree in Languages from USP and an Executive MBA from FIA.